GleamWall
中文EN

LEGN Legend Biotech Corp IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1801198 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY64.0%
TTM net income YoY-67.7%
TTM EPS YoY-68.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin61.4%
Operating margin—
Net margin-28.8%
FCF margin-12.5%
EBITDA margin—

Returns

ROE-29.1%
ROA-17.4%
ROIC (approx.)—
Asset turnover0.60x

Leverage & solvency

Liabilities / assets42.2%
Debt / equity0.32x
Current ratio1.96x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.34x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue2.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q12025-03-312024Q4*2024-12-312024Q3*2024-09-302024Q2*2024-06-302024Q12024-03-31
Income statement
Revenue$306.38M$272.33M$255.06M$195.05M$186.58M$160.21M$186.52M$93.99M
Cost of revenue$119.47M$113.26M$94.87M$69.50M$69.40M$52.51M$45.35M$49.10M
Gross profit$186.91M$159.07M$160.19M$125.56M$117.18M$107.69M$141.17M$44.89M
R&D expense$101.33M$113.15M$98.30M$101.92M$104.43M$95.52M$112.63M$100.96M
Operating income-$19.63M-$43.45M——-$79.31M-$70.36M——
Interest expense$5.48M$5.64M$5.22M$5.06M$5.15M$5.50M$5.48M$5.47M
Pretax income-$19.60M-$39.07M-$124.80M-$99.13M$40.51M-$120.89M-$17.97M-$59.79M
Income tax$11.22M$616,000$582,000$1.79M$14.23M$4.43M$226,000$5,000
Net income-$30.82M-$39.69M-$125.38M-$100.92M$26.28M-$125.32M-$18.20M-$59.79M
EPS (basic)—-0.11-0.34-0.27—-0.34-0.05-0.16
EPS (diluted)—-0.11-0.34-0.27—-0.34-0.05-0.16
Weighted avg. shares (diluted)—369.27M368.27M——366.56M365.20M—
Balance sheet
Cash & equivalents$901.90M$278.89M$266.59M$441.70M$286.70M$459.28M$201.25M$897.57M
Receivables$13.10M$1.24M$27.58M$369,000$6.40M$705,000$13.06M$3.31M
Inventory$32.00M$29.18M$35.59M$30.93M$23.90M$23.55M$18.87M$22.15M
Current assets$1.25B$1.24B$1.25B$1.22B$1.28B$1.35B$1.42B$1.41B
PP&E, netmay include right-of-use assets (IFRS)$116.30M$111.40M$106.38M$98.81M$99.30M$104.03M$105.02M$105.28M
Intangibles$1.90M—$2.14M$2.08M$2.20M$2.51M$2.77M$3.15M
Total assets$1.73B$1.71B$1.69B$1.62B$1.67B$1.74B$1.80B$1.78B
Current liabilities$636.40M$433.57M$265.48M$234.37M$277.70M$270.89M$294.30M$249.68M
Short-term debt$319.10M$142.87M——$0———
Long-term debt$0$171.93M$310.26M$305.75M$301.20M$296.62M$291.56M$286.40M
Total debt$319.10M$314.80M$310.26M$305.75M$301.20M$296.62M$291.56M$286.40M
Total liabilities$731.60M$701.69M$654.38M$597.90M$629.60M$619.72M$639.18M$611.05M
Shareholders' equity$1.00B$1.01B$1.04B$1.02B$1.04B$1.12B$1.16B$1.16B
Net debt-$582.80M$35.91M$43.68M-$135.96M$14.50M-$162.65M$90.31M-$611.17M
Cash flow statement
Operating cash flow-$12.21M$28.80M-$13.04M-$103.75M-$82.08M-$75.82M-$1.65M$15.52M
Capital expenditure$12.37M$5.00M$9.22M$2.00M$2.38M$2.06M$3.42M$6.24M
Free cash flow-$24.57M$23.80M-$22.27M-$105.76M-$84.46M-$77.89M-$5.07M$9.28M
Investing cash flow$638.49M-$20.00M-$165.53M$256.64M-$87.84M$329.08M-$695.63M-$396.15M
Financing cash flow-$647,000$670,000-$990,000$667,000-$333,000$4.25M$955,000$831,000
Stock-based compensation$14.94M$15.02M$18.70M$15.95M$13.39M$15.11M$21.74M$18.70M

Free plan shows the latest 8 periods; Pro shows all 14 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.